US/UK/Canada

Share

Contacts

  • Morten Henneveld

    CEO


    +46 18 55 39 93

    • Links

    Pick a time period -
    Tags ( Active)

    OssDsign Catalyst 1cc is now launched and available in the U.S. market

    Uppsala, 10 January 2023. OssDsign AB (publ.) announces today that the company has now commenced the launch of a new size of OssDsign Catalyst in the U.S market. The additional volume option of 1 cubic centimeter (cc) is now fully available on the market and completes the existing product range of 10, 5 and 2,5 cc, thereby broadening the access to new procedures in both cervical spine and smaller extremities.“We are excited to announce that our new smaller size of OssDsign Catalyst is now available in the U.S. We see a rapidly growing interest in our innovative nanosynthetic bone graft, and

    First patients in the U.S. treated with OssDsign Catalyst

    Uppsala, October 7, 2021, OssDsign AB (publ) today announces that the first patients in the U.S. have been treated with OssDsign Catalyst – a synthetic bone graft composed from a patented nanocrystalline solution that stimulates the formation of healthy bone tissue after spinal fusion surgery.OssDsign Catalyst received market clearance from the Food and Drug Administration (FDA) in 2020 and was launched on the American market in august 2021. The addressable market for synthetic bone grafts after spinal fusion surgeries is valued at USD 2.6 billion and has a CAGR of approximately 7% during

    OssDsign Catalyst now available on the U.S. market

    Uppsala, Sweden, 08:00 CET, 16 August 2021 – OssDsign today announces that OssDsign Catalyst has been launched and is now ready for sale in the U.S. This marks an important step in the company’s strategy of entering the highly scalable bone graft market with its innovative nanosynthetic bone graft that stimulates the formation of healthy bone tissue.Nearly 80 percent of all Americans experience low back pain at some point in their lives and more than 1.5 million will undergo spinal fusion surgery. Approximately 20 percent of these surgeries are unsuccessful due to the lack of proper fusion

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media